Is acotinib a targeted drug or a chemotherapy drug?

Acalabrutinib is a targeted therapy drug, not a traditional chemotherapy drug. Targeted therapy drugs act on specific molecular targets within cancer cells to inhibit or block the growth, proliferation and metastasis of cancer cells while reducing damage to normal cells.

Acotinib is a type of BTK inhibitor that mainly acts on the B cell receptor signaling pathway. BTK is a key tyrosine kinase in B cells and plays an important role in the development, maturation and function of B cells. By selectively inhibiting the activity of BTK, acotinib blocks the signaling pathway of abnormal B cells, thereby inhibiting the growth and proliferation of leukemia and lymphoma cells.

Compared with traditional chemotherapy drugs, targeted therapy drugs have higher selectivity and targeting, can act on tumor cells more accurately, reduce damage to normal cells, and reduce toxic and side effects during treatment. In addition, targeted therapies are often better suited to individualized treatment needs, as their efficacy may be affected by the individual genetic and molecular characteristics of the patient.

However, it should be noted that although targeted therapy drugs have made significant progress in cancer treatment, there are also some limitations, such as drug resistance, adverse reactions, etc. Therefore, when using acotinib or other targeted therapies, it is still necessary to closely monitor the patient's treatment response and adverse events in order to adjust the treatment plan in a timely manner to ensure that the patient obtains the best therapeutic effect.